Multicenter, cross-sectional study of the economic burden of multiple sclerosis and cost-driving factors
Expert Review of Pharmacoeconomics & Outcomes Research · 26.11.2025 · 25 (10) · 1489-1496
DOI: 10.1080/14737167.2025.2539840 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, online erschienen am 25.07.2025. Verfasst von Moustafa Berrichi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Tlemcen, Tlemcen, Algeria. Hauptthemen laut MEDLINE: Cost of Illness, Multiple Sclerosis, Health Care Costs, Quality of Life. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Multiple sclerosis (MS) is a chronic neurodegenerative disease impacting young adults, reducing quality of life and imposing economic burdens. OBJECTIVES: This study estimated MS costs in Algeria from a societal perspective, analyzed cost variations by disease severity, and provided insights for enhancing MS management and healthcare planning. METHODS: A cross-sectional, bottom-up cost-of-illness study used a validated questionnaire to collect demographic, clinical, and socioeconomic data from MS patients. Data included disease-modifying therapy (DMT) use, MS course, and EDSS scores. Direct costs (medical and non-medical) and indirect costs (productivity losses from absenteeism and early retirement) were calculated. Cost drivers were analyzed using generalized linear models. RESULTS: Among 354 patients, the total annual societal cost per MS patient was $9,636.5 (95% CI: 9101.2 -10,178), with a mean EDSS score of 3.1 (SD 2.1). Direct costs accounted for 93.31%, with DMTs comprising 94.42% of direct medical costs. Costs rose with disease severity, from $8,697.9 (95% CI: 8060.9-9326.8) for mild MS to $12,450.8 (95% CI: 10137.2 -14,773.6) for severe MS (p < 0.001). CONCLUSIONS: This study highlights MS's economic burden in Algeria, with DMTs as the primary cost driver. Optimized resource allocation and cost-effective DMT strategies are essential to improve MS care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, University of Tlemcen, Tlemcen, Algeria.
- Department of Medicine, University of Tlemcen, Tlemcen, Algeria.
- Department of Pharmacy, University of Oran, Oran, Algeria.
ORCID-Profile: Moustafa Berrichi
Zitieren
APA
Berrichi, M., Barka-Bedrane, Z., Osmani, A., Belahcen, K., Hafsi, B., Messaoudi, I., Selka, M. A., & Toumi, H. (2025). Multicenter, cross-sectional study of the economic burden of multiple sclerosis and cost-driving factors. Expert Review of Pharmacoeconomics & Outcomes Research, 25(10), 1489-1496. https://doi.org/10.1080/14737167.2025.2539840
Vancouver
Berrichi M, Barka-Bedrane Z, Osmani A, Belahcen K, Hafsi B, Messaoudi I, et al. Multicenter, cross-sectional study of the economic burden of multiple sclerosis and cost-driving factors. Expert Review of Pharmacoeconomics & Outcomes Research. 2025;25(10):1489-1496. doi:10.1080/14737167.2025.2539840
BibTeX
@article{Berrichi2025,
author = {Berrichi, Moustafa and Barka-Bedrane, Zahira and Osmani, Ahlam and Belahcen, Karima and Hafsi, Bouchra and Messaoudi, Ines and Selka, Mohammed Adil and Toumi, Houari},
title = {Multicenter, cross-sectional study of the economic burden of multiple sclerosis and cost-driving factors},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2025},
volume = {25},
number = {10},
pages = {1489--1496},
doi = {10.1080/14737167.2025.2539840}
}
EUVIMED